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due to a higher incidence of ductal carcinoma in situ with 
microcalcifications and low neoangiogenesis. A sensitiv-
ity close to 95 % can be obtained only using mammogra-
phy as an adjunct to MRI. Considering the available evi-
dence, women who underwent CRT before 30 receiving a 
cumulative dose ≥10 Gy should be invited after 25 (or, at 
least, 8 years after CRT) to attend the following program: 
1. interview about individual risk profile and potential of 
breast imaging; 2. annual MRI using the same protocol rec-
ommended for women with hereditary predisposition; 3. 
Abstract Women who underwent chest radiation therapy 
(CRT) during pediatric/young-adult age (typically, lym-
phoma survivors) have an increased breast cancer risk, in 
particular for high doses. The cumulative incidence from 
40 to 45 years of age is 13–20 %, similar to that of BRCA 
mutation carriers for whom contrast-enhanced magnetic 
resonance imaging (MRI) is recommended. However, in 
women who underwent CRT, MRI sensitivity is lower (63–
80 %) and that of mammography higher (67–70 %) than 
those observed in women with hereditary predisposition, 
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annual bilateral two-view full-field digital mammography 
or digital breast tomosynthesis (DBT) with synthetic 2D 
reconstructions. Mammography and MRI can be performed 
at once or alternately every 6 months. In the case of MRI or 
contrast material contraindications, ultrasound will be per-
formed instead of MRI. Reporting using BI-RADS is rec-
ommended. At the age for entering population screening, 
the individual risk profile will be discussed with the woman 
about opting for only mammography/DBT screening or for 
continuing the intensive protocol.
Riassunto Le donne sottoposte a radioterapia toracica 
(RTT) in età pediatrica o giovane-adulta, tipicamente per 
linfoma di Hodgkin, hanno un rischio aumentato di svilup-
pare tumore mammario (TM), in particolare quelle trattate 
con RTT ad alte dosi. L’incidenza cumulativa di TM tra 40 
e 45 anni è del 13–20 %, simile a quella delle donne BRCA 
mutate, per le quali è ormai consolidata l’indicazione alla 
risonanza magnetica (RM) con mezzo di contrasto (MdC) 
annuale. Tuttavia, rispetto agli studi di screening delle 
donne ad elevato rischio eredo-familiare, nelle donne sot-
toposte a RTT si è osservata una sensibilità relativamente 
maggiore della mammografia e relativamente minore della 
RM con MdC, correlate alla maggiore incidenza di car-
cinoma duttale in situ con microcalcificazioni e minore 
neoangiogenesi. Sulla base dell’evidenza disponibile, le 
donne sottoposte a RTT prima dei 30 anni di età con dose 
cumulativa ≥10 Gy dovrebbero essere invitate a partire dai 
25 anni o almeno da 8 anni dopo la RTT a partecipare a 
un programma di sorveglianza che preveda: 1. colloquio 
informativo finalizzato all’informazione della donna sul 
proprio livello di rischio correlato alla RTT e ad eventuali 
altri fattori e sul potenziale delle tecniche di imaging; 2. 
RM con MdC bilaterale annuale con il medesimo proto-
collo raccomandato per lo screening delle donne ad elevato 
rischio eredo-familiare; 3. mammografia digitale bilaterale 
annuale o tomosintesi con ricostruzioni 2D (proiezioni 
cranio-caudale e medio-laterale obliqua). Mammografia e 
RM possono essere eseguite contestualmente o alternate a 
cadenza semestrale. Reperti ed indagini mammografiche 
e RM saranno classificati secondo la scala categoriale BI-
RADS. Nel caso di controindicazioni alla RM o alla som-
ministrazione di MdC paramagnetico, sarà eseguita ecogra-
fia mammaria bilaterale anche in presenza di mammografia 
negativa, contestualmente alla mammografia o con alter-
nanza semestrale. Al raggiungimento dell’età per l’invito 
ai programmi di screening organizzato, il profilo di rischio 
della donna sarà rivalutato e discusso al fine di decidere se 
optare per l’adesione al protocollo di screening basato su 
mammografia (eventualmente tomosintesi) annuale o bien-
nale o per la prosecuzione dello screening intensivo con 
mammografia e RM annuali. Si raccomanda che il presente 
protocollo di sorveglianza sia effettuato presso centri di 
radiologia senologica che rispettino i requisiti quali/quan-
titativi definiti da linee-guida internazionali e che tutti i dati 
relativi all’applicazione del protocollo, ivi compresi i can-
cri d’intervallo, siano raccolti mediante database informa-
tizzato al fine di consentire analisi di performance diagnos-
tica e di efficacia su scala multicentrica.
Keywords Breast cancer · Screening · Lymphoma 
survivors · MRI
Background and rationale
Women who underwent chest radiation therapy (CRT) dur-
ing pediatric/young-adult age (typically those treated for 
Hodgkin lymphoma) have an increased breast cancer (BC) 
risk, in particular those who received mantle CRT with 
high doses. However, an increased risk is also associated 
with RT with moderate doses for non-Hodgkin lymphoma, 
Wilms tumor, leukemia, bone tumors, neuroblastoma or 
soft tissue sarcoma [1]. The cumulative BC incidence from 
40 to 45 years of age in women who underwent CRT is 
13–20 %, higher than the incidence observed in the young 
female general population and similar to that of BRCA 
mutation carriers [1, 2]. The age at which CRT was per-
formed and the radiation dose impact on the risk and is 
higher for high doses delivered between 10 and 16 years of 
age. BC is diagnosed on average about 15 years after CRT 
at about 40 years [3], compared with a mean age of about 
61 years in the general female non-exposed population [1]. 
Breast cancers in women who underwent CRT are similar 
to those encountered in the general female population with 
regard to histopathologic subtype, receptor status, lym-
phatic invasion and nodal involvement, which play in favor 
of a potential role of early diagnosis. Conversely, BCs in 
women who underwent CRT exhibit a more extreme pref-
erential localization at the upper external quadrants than 
that observed in women with hereditary predisposition (67 
vs. 48 %, respectively). Moreover, in these women the pos-
sibilities of treatment of BC mostly exclude radiation ther-
apy and chemotherapy with doxorubicin [4].
For women who underwent CRT, international guide-
lines [2, 5, 6] recommend annual mammography and con-
trast-enhanced magnetic resonance imaging (MRI), starting 
from 25 years of age or, for those women who had CRT 
before 30 years, 8 years after the end of treatment. The 
rationale behind is the similar BC incidence at a young age 
for women who had CRT and for women with hereditary 
predisposition to BC, associated with the relatively lower 
sensitivity of mammography, also related to the need to 
start at a young age, and the higher sensitivity of MRI [7].
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The availability and application of guidelines/recom-
mendations for the surveillance of women who underwent 
CRT is relevant for good clinical practice. In fact, BC risk 
of these women and, as a consequence, the importance of 
breast surveillance is frequently underestimated. In the 
USA, a study published in 2009 [8] reported that of 551 
women with previous CRT, 47 % of those 25–39 years of 
age never had a mammogram and only 37 % had biannual 
screening mammography; the same percentages were 8 
and 53 % between 40 and 50 years of age. Importantly, the 
screening rate was higher in the presence of a specific med-
ical recommendation. The last point highlights the need for 
clear statements from medical bodies.
Before the introduction of MRI, the breast surveillance 
of women with previous CRT included annual physical 
examination and mammography [9]. This protocol allowed 
for detecting 60 % of BC in the pre-invasive phase or at T1 
stage [10–14]. Two prospective [15, 16] and two retrospec-
tive studies [17, 18] compared mammography and MRI. The 
sensitivity ranged from 67 to 70 % for mammography, from 
63 to 80 % for MRI, with a 92 % sensitivity reached only 
in one retrospective study, with a very small sample size for 
MRI [18]. Importantly, in women who underwent CRT, MRI 
sensitivity is relatively lower (63–80 %) and that of mam-
mography relatively higher (67–70 %) than those observed in 
women with hereditary predisposition, due to a higher inci-
dence of ductal carcinoma in situ with microcalcifications 
[19] and low neoangiogenesis. A sensitivity close to 95 % can 
be obtained only using mammography as an adjunct to MRI.
An expert panel [20] recently compared the recommen-
dations proposed by the following working groups: North 
American Children’s Oncology Group (COG), Dutch Child-
hood Oncology Group (DCOG), Scottish Intercollegiate 
Guidelines Network (SIGN), and UK Children’s Cancer and 
Leukaemia Group (UKCCLG). As a result of this compari-
son, a series of “harmonized recommendations” were pro-
vided: physicians, health-care providers, and women who 
had CRT should be informed of the treatment-related BC 
risk (strong recommendation); surveillance is recommended 
for doses ≥20 Gy (strong recommendation); surveillance is 
recommended for doses between 10 and 19 Gy, taking into 
account the clinical context and further risk factors (moderate 
recommendation); surveillance may be reasonable for doses 
between 1 and 9 Gy, taking into account the clinical context 
and further risk factors (weak recommendation); surveillance 
implies annual check from 25 years of age or, at least, 8 years 
after CRT up to 50 years of age using mammography, MRI or 
both of them (strong recommendation); physical examination 
may be recommended in countries where only clinical sur-
veillance is available (weak recommendation).
Recommendations for breast surveillance 
of women who underwent CRT
Considering the available evidence for women who 
underwent CRT before 30 years, a cumulative dose 
≥10 Gy should be irecommended after 25 years (or, 
at least, 8 years after CRT) and to attend the following 
program:
1. dedicated interview about individual risk profile and 
potential of different breast imaging modalities in 
this specific setting according to this document or 
other recommendations [5, 6, 21–23];
2. annual contrast-enhanced MRI using the same proto-
col recommended for women with hereditary predis-
position [2, 23];
3. annual bilateral two-view full-field digital mammog-
raphy or digital breast tomosynthesis (DBT) with 
synthetic 2D reconstructions.
Mammography and MRI can be performed at once (pref-
erably during only one visit) or alternately every 6 months, 
considering the local conditions. Reporting using BI-RADS 
[24] for individual findings and overall is recommended. In 
the case of BI-RADS diagnostic category 1 o 2 after MRI plus 
mammography, the woman will be sent to the next screening 
event, taking into consideration the lack of evidence in favor 
of ultrasound if both MRI and mammography are negative. In 
the case of BI-RADS ≥3, the radiologist will evaluate which 
workup is needed, including additional mammographic 
views, DBT (if not already performed), ultrasound, imaging-
guided core or vacuum-assisted needle biopsy.
On reaching the age for entering a population screening 
program, the individual risk profile will be discussed with 
the woman to opt for the only mammography/DBT screen-
ing or for continuing the intensive protocol including MRI.
We strongly recommend this surveillance protocol 
to be conducted at breast imaging centers with respect 
to the quantitative and qualitative requirements defined 
by international guidelines [2, 25] and that all data and 
results provided by the application of this protocol, 
including interval cancers, are stored on electronic data-
bases. This will allow for future analyses of diagnostic 
performance and clinical efficacy on a multicenter scale.
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